1 Seropositivity to Nucleoprotein to detect SARS-CoV-2 infections: a tool to

2 detect breakthrough infections after COVID-19 vaccination

Lotus L. van den Hoogen¹*, Gaby Smits¹, Cheyenne C.E. van Hagen², Denise Wong², Eric R.A. Vos², 3 Michiel van Boven², Hester E. de Melker², Jeffrey van Vliet¹, Marjan Kuijer¹, Linde Woudstra¹, Alienke 4 J. Wijmenga-Monsuur¹, Corine H. GeurtsvanKessel³, Susanne P. Stoof⁴, Daphne Reukers⁵, Lisa A. 5 Wijsman⁵, Adam Meijer⁵, Chantal B.E.M. Reusken⁵, Nynke Y. Rots¹, Fiona R.M. van der Klis¹, Robert S. 6 van Binnendijk¹, Gerco den Hartog¹ 7 8 1. Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public 9 Health and the Environment (RIVM), Bilthoven, The Netherlands 2. Centre for Infectious Diseases, Epidemiology and Surveillance, National Institute for Public 10 Health and the Environment (RIVM), Bilthoven, The Netherlands 11 3. Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands 12 13 4. Department of Medical Microbiology Comicro, Dijklander ziekenhuis, Hoorn, The Netherlands 14 5. Centre for Infectious Diseases Research, Diagnostics and Laboratory Surveillance, National 15 Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands 16 17 2,997 18 Word count: 19 Inserts: 2 Tables; 2 Figures 20 21 * Corresponding author: 22 lotus.van.den.hoogen@rivm.nl 23 Centre for Immunology of Infectious Diseases and Vaccines (IIV) 24 National Institute of Public Health and the Environment (RIVM) 25 Antonie van Leeuwenhoeklaan 9, 26 3721 MA Bilthoven, 27 The Netherlands

28 Abstract

29 Background

- 30 With COVID-19 vaccine roll-out ongoing in many countries globally, monitoring of breakthrough
- 31 infections is of great importance. Antibodies persist in the blood after a severe acute respiratory
- 32 syndrome coronavirus 2 (SARS-CoV-2) infection. Since COVID-19 vaccines induce immune response
- 33 to the Spike protein of the virus, which is the main serosurveillance target to date, alternative
- 34 targets should be explored to distinguish infection from vaccination.

35 Methods

- 36 Multiplex immunoassay data from 1,513 SARS-CoV-2 RT-qPCR-tested individuals (352 positive and
- 37 1,161 negative) with a primary infection and no vaccination history were used to determine the
- accuracy of Nucleoprotein-specific immunoglobulin G (IgG) in detecting past SARS-CoV-2 infection.
- 39 We also described Spike S1 and Nucleoprotein-specific IgG responses in 230 COVID-19 vaccinated
- 40 individuals (Pfizer/BioNTech).

41 Results

- 42 The sensitivity of Nucleoprotein seropositivity was 85% (95% confidence interval: 80-90%) for mild
- 43 COVID-19 in the first two months following symptom onset. Sensitivity was lower in asymptomatic
- 44 individuals (67%, 50-81%). Participants who had experienced a SARS-CoV-2 infection up to 11
- 45 months preceding vaccination, as assessed by Spike S1 seropositivity or RT-qPCR, produced 2.7-fold
- higher median levels of IgG to Spike S1 \geq 14 days after the first dose as compared to those unexposed
- 47 to SARS-CoV-2 at ≥7 days after the second dose (p=0.011). Nucleoprotein-specific lgG concentrations
- 48 were not affected by vaccination in naïve participants.

49 Conclusions

- 50 Serological responses to Nucleoprotein may prove helpful in identifying SARS-CoV-2 infections after
- 51 vaccination. Furthermore, it can help interpret IgG to Spike S1 after COVID-19 vaccination as
- 52 particularly high responses shortly after vaccination could be explained by prior exposure history.
- Keywords: COVID-19; SARS-CoV-2; Nucleoprotein; serosurveillance; immunoglobulin G; multiplex
 immunoassay

55 Introduction

Since late 2020, multiple countries have initiated vaccine roll-out against COVID-19 which is caused 56 57 by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. Breakthrough infections have 58 been reported shortly after completion of the vaccination regimen [2]. Although COVID-19 vaccines 59 were developed to prevent severe disease and mortality and not to provide sterile protection, it will 60 remain important to monitor the frequency of breakthrough infections as well as their transmission 61 potential, specifically as new SARS-CoV-2 variants emerge [3]. During the acute phase of an 62 infection, molecular (RT-qPCR) and antigen tests are used to confirm symptomatic and 63 asymptomatic breakthrough infections, i.e. after contact tracing or travel to a high-risk area. 64 However, asymptomatic persons who do not seek testing will likely be missed. To ensure a complete 65 picture of the frequency of breakthrough infections for surveillance purposes, frequent RT-qPCR 66 testing would be needed which is time- and labor intensive as well as burdensome to individuals. 67 Serological assays can identify specific antibodies which indicate previous infection with 68 SARS-CoV-2. SARS-CoV-2 serostatus can be determined high-throughput with multiplex 69 immunoassays (MIA [4]), irrespective of the presence of clinical symptoms. Immunoglobulin G (IgG) 70 antibodies persist for months after infection which widens the window of detection as compared to 71 RT-qPCR and antigen tests [5]. This should provide a more accurate estimate of ongoing transmission 72 in the general population. However, since the main serological marker used to date for SARS-CoV-2 is also the vaccine target, Spike S1 or RBD, alternative serological targets should be explored to 73 74 distinguish past infection from vaccination. Nucleoprotein is one of the structural immunogenic 75 SARS-CoV-2 proteins. Others have reported sensitivity estimates ranging from 70% to 96% with 76 specificity at \geq 95%, depending the assay and reference population used [6-9]. Reference populations 77 consisted of healthcare workers or hospitalized patients, which are not representative for the 78 general population. Moreover, patients with severe symptoms produce higher antibody levels than 79 those with mild or no symptoms which leads to overestimation of sensitivity estimates [5, 10]. Hence, the reliability of Nucleoprotein to detect mild or asymptomatic infections, which represent 80 81 the majority of COVID-19 cases [11, 12], is still unknown. 82 We previously described a bead-based detection method for simultaneous IgG detection to 83 Spike S1 and Nucleocapsid [4]. In this study we aimed to determine the accuracy of seropositivity to 84 Nucleoprotein and Spike S1 by time since RT-qPCR-confirmed infection with mild or asymptomatic

SARS-CoV-2 using a prospective household survey as well as a nationwide population survey.

86

85

87 Methods

88 Study design and population

89 Household cohort of infected and noninfected participants

90 A prospective cohort study was performed in households where one household member had tested 91 positive for SARS-CoV-2 to determine within household transmission [13]. Patients with a RT-qPCR-92 confirmed SARS-CoV-2 infection (=index case) in the Municipal Health Service (GGD) Utrecht region, 93 central Netherlands, were invited to participate with their household if they had at least one child under the age of 18 living at home. Households from 54 index cases were enrolled from March 24th 94 to May 24th 2020 (with a total of 242 participants). Households were excluded if one or more of the 95 96 household contacts did not want to participate in the study upfront. Furthermore, infants under the 97 age of 1 were excluded. Most families were those of healthcare workers, for whom RT-qPCR testing 98 was available at enrolment during the first pandemic wave (March/April 2020). Study nurses visited 99 the families at their household within 24 hours after inclusion (T1), 2-3 weeks after inclusion (T2) 100 and 4-6 weeks after inclusion (T3) to collect a venous blood sample for serological testing as well as 101 a naso- and oropharyngeal swab, oral fluid and they supplied a feces collection kit. At 9-11 months 102 after T1 (T5), another venous blood sample was collected at which point some of the participants 103 had been COVID-19 vaccinated. Participants filled out a guestionnaire at each sampling timepoint 104 including data on demographic factors, symptoms and symptom onset, and vaccination data where 105 applicable (brand product, number of vaccinations and their dates). The study was ethically 106 approved by the Medical-Ethical Review Committee of the University Medical Center Utrecht 107 (NL13529.041.06). All participants above the age of 12 gave written informed consent. Both parents 108 or guardians of participating children below the age of 16 also gave written informed consent for 109 participation of the child.

110 National cohort of noninfected, convalescent and vaccinated individuals

111 Serum samples were collected in an ongoing, nationwide longitudinal serosurveillance study; the 112 PIENTER Corona (PICO) cohort study described by Vos et al. [14, 15]. Briefly, the PICO study 113 emanated from a large-scale nationwide cross-sectional study performed in 2016-17 (PIENTER-3 114 [16]). Participants from the PIENTER-3 study who had consented to follow-up were invited to 115 participate in the PICO study in April 2020 [14] and the cohort was extended with an additional nationwide random sample in June 2020 [15]. Two more rounds have been completed in October 116 117 2020 and February 2021. Each round participants were requested to return a self-collected finger-118 prick blood sample in a microtainer by mail and complete a guestionnaire. Questions covered 119 sociodemographic factors, clinical data (type and date of onset of symptoms), virological findings if 120 applicable (SARS-CoV-2 RT-gPCR testing, and date and result of testing; February 2021 round only) 121 and data on COVID-19 vaccination if applicable (brand product, number of vaccinations and their

- dates; February 2021 round only). The study was ethically approved by the Medical Research Ethics
- 123 Committees United MEC-U and registered under trial number NL8473. All participants above the age
- 124 of 12 gave written informed consent. Both parents or legal guardians of participating children below
- 125 the age of 16 years also gave written informed consent for participation of the child.

126 Laboratory methods

- 127 SARS-CoV-2 RT-qPCR testing in the household cohort
- 128 All available samples in the household cohort were tested for presence of SARS-CoV-2 as previously
- described [13, 17]. The results of the naso- and oropharyngeal swab, oral fluid and feces specimens
- at T1 or T2 were combined to one result: RT-qPCR negative (all negative) or RT-qPCR positive (any
- 131 positive). Index cases were considered RT-qPCR positive even if they tested negative at T1 and T2 as
- they would have tested RT-qPCR positive with local health authorities prior to enrolment in the
- 133 study.
- 134 Multiplex immunoassay for Immunoglobulin G detection in the household and national cohorts
- 135 Serum was separated from blood clot and stored at -20°C until analysis. Total IgG to Spike S1 and
- 136 Nucleoprotein was measured with a MIA as previously described [4]. Median fluorescence intensity
- 137 measurements were expressed as binding antibody units per milliliter (BAU/ml) using 5-parameter
- 138 logistic interpolation of the International Standard for human anti-SARS-CoV-2 immunoglobulin
- 139 (20/136 NIBSC standard) [18].

140 Statistical analyses

141 All statistical analyses were performed in R version 4.0.2 [19]. Calculation of seropositivity thresholds 142 and associated assay performance is detailed in the Supplementary Methods. Sensitivity of 143 seropositivity to Nucleoprotein and Spike S1 in detecting a past RT-qPCR-confirmed SARS-CoV-2 144 infection was determined in 1) hospitalized COVID-19 patients (Intensive Care Unit or ward), 2) mild 145 COVID-19 patients (i.e., with COVID-19-related symptoms but not hospitalized), and 3) individuals 146 with an asymptomatic infection. Specificity was determined in those who tested RT-gPCR negative. 147 COVID-19-related symptoms were classified as fever, coughing, shortness of breath, loss of taste or 148 smell, sore throat, headache, pain while breathing, runny nose, muscle ache, diarrhoea, (extreme) 149 tiredness and/or nausea.

Data from the national and household cohort were analyzed jointly. We did not include repeated samples from the same individuals. Unvaccinated participants who underwent SARS-CoV-2 confirmatory testing between two weeks and 6 months prior to serological sampling were included in the study. Exclusion criteria were incomplete symptom data, serological evidence of SARS-CoV-2

154 exposure prior to testing or other testing than RT-gPCR such as rapid antigen tests (Supplementary 155 Figure 2). The time since onset of symptoms was used to determine sensitivity over time since 156 infection. For asymptomatic participants in the national cohort, the time since RT-qPCR testing date 157 was used. In the household cohort, the time since onset of symptoms or diagnosis date for the index 158 case was used if the time since onset of symptoms was unknown or in asymptomatic participants. 159 For reference, sera from 27 hospitalized COVID-19 cases between 14 days and 2 months after onset 160 of symptoms were analysed: 7 patients in the household cohort (Supplementary Figure 2A), 10 161 patients from the Erasmus Medical Centre in Rotterdam (Medical Ethical Committee number METC 162 06/282) and 10 patients from the Dijklander hospital in Hoorn. 163 To describe IgG to Spike S1 and Nucleoprotein in a COVID-19 vaccinated study population, 164 data from the two cohorts were also combined (Supplementary Figure 2). Participants who reported 165 to have completed one or two doses of COVID-19 vaccination were included. As nearly all 166 participants had received Pfizer/BioNTech, participants with other vaccine brands were excluded. 167 Furthermore, participants with incomplete vaccination information, such as vaccination dates, were 168 excluded. Past infection with SARS-CoV-2 was based on RT-gPCR confirmation in the household 169 cohort and Spike S1 seroconversion in a previous study round or self-reported RT-aPCR testing 170 where available in the national cohort. 171 Sensitivity and specificity estimates, and their 95% confidence intervals (CIs) were calculated 172

applying Receiver Operating Characteristic (ROC) curves using the pROC package in R (version 1.16.2
[20]). Cls were computed with 2,000 stratified bootstrap replicates. The Wilcoxon-Mann-Whitney
test was used to compare IgG measurements between vaccinated participants who did vs. those
who did not experience a prior SARS-CoV-2 infection.

176

177 Results

178 SARS-CoV-2 RT-qPCR-tested study population

179 A total of 352 mild and asymptomatic participants had tested RT-qPCR positive for SARS-CoV-2 and

180 1,161 negative (Table 1). The majority was female (61% of the RT-qPCR positives and 61% of the RT-

- 181 qPCR negatives) and in the age category 22-65 years old (71% of the RT-qPCR positives and 68% of
- 182 the RT-qPCR negatives). Most of the RT-qPCR positives experienced mild COVID-19-related
- symptoms (90%) compared to 56% of the RT-qPCR negatives, while 10% of the RT-qPCR positives
- and 44% of the RT-qPCR negatives were asymptomatic.

185 Nucleoprotein and Spike S1 seropositivity to detect past SARS-CoV-2 infection

186 Nucleoprotein and Spike S1 IgG measurements by SARS-CoV-2 RT-gPCR status and symptom status 187 are shown in Figure 1A. Sensitivity of Nucleoprotein was highest in hospitalized COVID-19 patients 188 (100%) between two weeks and two months post onset of symptoms as compared to mild COVID-19 189 (79%, 95% CI: 75-84%) or asymptomatic SARS-CoV-2 (67%, 50-81%) between two weeks and six 190 months following symptom onset/infection (Figure 1B). Seropositivity to Spike S1 showed higher 191 sensitivity estimates (i.e., hospitalized: 100%, mild COVID-19: 89%, 85-92%, asymptomatic SARS-192 CoV-2: 72%, 56-86%). Sensitivity of Nucleoprotein for mild COVID-19 was highest shortly after 193 infection: 85% (79-91%) at 2 weeks to 2 months following the onset of symptoms to 79% (70-86%) at 194 3-4 months and 59% (44-72%) at 5-6 months. This decline was faster than that seen for Spike S1 195 (from 90%, 85-94%, to 90%, 83-95% to 80%, 67-91%; Figure 1C).

196Specificity in RT-qPCR negative tested persons was 97% (96-98%) for Nucleoprotein and 98%

197 (97-99%) for Spike S1 (Figure 1B). For persons who seroconverted to either Nucleoprotein or Spike

198 S1 within the RT-qPCR-negative selection (n=46), 19 had seroconverted to Nucleoprotein only (41%),

199 9 to Spike S1 only (20%) and 18 to both Nucleoprotein and Spike S1 (39%).

200 Spike S1 and Nucleoprotein IgG kinetics after COVID-19 vaccination with Pfizer/BioNTech

- 201 Of the 230 Pfizer/BioNTech vaccinated participants, 118 had received two doses at the time of
- 202 sampling (51%), 172 were female (75%) and 177 were 18-65 years old (77%) vs. 53 who were >65
- 203 years old (23%) (Table 2). In previously naïve individuals (n=179), IgG to Spike S1 showed a

204 homogenous response between individuals over time since vaccination (Figure 2A). After two weeks,

205 96% of the previously naïve individuals had seroconverted to Spike S1 (126/131, Figure 2A). The

206 majority was seronegative for Nucleoprotein (93%, 122/131; Figure 2B). Of the nine seropositive

207 individuals, four were already seropositive for Nucleoprotein prior to vaccination but not for Spike

- 208 S1. Participants who had experienced a SARS-CoV-2 infection preceding vaccination, produced 2.7-
- fold higher median levels of IgG to Spike S1 ≥14 days after the first dose as compared to those
- unexposed to SARS-CoV-2 at ≥7 days after the second dose (6,480 vs. 2,438 BAU/ml, p=0.011, Figure
- 211 2C).

212Of the COVID-19 vaccinated participants with evidence for a previous SARS-CoV-2 infection,21313 experienced symptom onset less than five months prior to sampling. Ten of these 13 had

seroconverted to Nucleoprotein (77%, 54-100%), while nearly all were symptomatic during their

215 infection (92%, 12/13). At 8-11 months post symptom onset, 45% (29-61%) were seropositive for

216 Nucleoprotein while 82% (31/38) had been symptomatic during their infection.

217

218 Discussion

219 As COVID-19 vaccines induce immune responses to the Spike protein, alternative serological targets 220 need to be considered for serosurveillance of SARS-CoV-2 breakthrough infections. Here, we showed 221 that seropositivity to Nucleoprotein can detect mild COVID-19 with a sensitivity of 85% between two 222 weeks and two months following symptom onset compared to 90% for Spike S1. At 3-4 months post 223 symptom onset, sensitivity declined to 79% for Nucleoprotein while it remained 90% for Spike S1. 224 Several publications have focused on the sensitivity of Nucleoprotein to detect past RT-225 aPCR-confirmed SARS-CoV-2 infections with estimates ranging from 70% to 96% [6-9]. The wide 226 range in the observed sensitivity estimates is likely due to differences in the used reference 227 population, often consisting of hospitalized patients or healthcare workers with COVID-19, and 228 differences related to the applied antibody detection platforms. Few have stratified results by 229 symptomatic status of the reference populations or time since onset of symptoms [7]. This while 230 breakthrough infections are expected to be even more frequently mild or asymptomatic than 231 primary infections. In mildly symptomatic persons (healthcare workers), Mariën et al. reported a 232 sensitivity of 70% within six weeks and 85% more than five months after symptom onset [7]. We also 233 reported a sensitivity of 85% in mildly symptomatic patients between two weeks and two months 234 after symptom onset though we saw a decline to 59% at 5-6 months after symptom onset. In 235 persons with an asymptomatic SARS-CoV-2 infection in our study, sensitivity of Nucleoprotein was 236 67%; insufficient numbers were available to stratify this estimate further by time since infection. Our 237 estimate for Spike S1 sensitivity in asymptomatic participants (72%; 26/36) was similar to that 238 recently published by Vanshylla et al. combining IgG and IgA responses (77%; 34/44) [21]. Although 239 Nucleoprotein sensitivity was lower in asymptomatic individuals, few to none of these individuals 240 would have been identified by passive surveillance using RT-qPCR or antigen tests as the absence of 241 symptoms would limit chances of seeking diagnosis. 242

Sensitivity decreased to 79% at 3-4 months following infection, a 8% seroreversion in 2 243 months. Choudhry et al. reported 31% seroreversion for Nucleoprotein IgG after three months in 244 seroconverted healthcare workers in the United Kingdom using rapid IgG/IgM tests [22]. Others 245 have likewise shown that Nucleoprotein IgG antibodies decline on average 1.5-2 times faster than 246 those to Spike S1 [10, 23]. The higher rate of seroreversion for Nucleoprotein compared to Spike S1, 247 means that regular serological measurements is recommended to ensure detection of breakthrough 248 infections (e.g. 2-3 monthly intervals). The serological response to Nucleoprotein may vary more 249 following COVID-19 vaccination as partial immunity might limit viral replication and thus exposure of 250 the immune system to the viral Nucleoprotein. Asymptomatic and mild cases that might be missed 251 by RT-qPCR or serological testing are unlikely to pose a risk of development of disease requiring 252 hospitalization. However, they might still contribute to transmission of the virus.

253 Previous specificity estimates for bead-based assays were \geq 97% based on pre-pandemic 254 controls [7-9]. Here we likewise showed that 97% of the RT-qPCR-negative population was 255 seronegative for Nucleoprotein. However, presence of SARS-CoV-2 could have been missed in our 256 study due to no detectable SARS-CoV-2 RNA at the time of sampling or incorrect sampling thus 257 lowering specificity. 18 out of 37 Nucleoprotein seropositive persons also seroconverted to Spike S1 258 which strengthens the hypothesis that these samples represent participants not being sampled 259 optimally for RT-qPCR. The performance of an assay is a trade-off between sensitivity and specificity. 260 As we expect the prevalence of breakthrough infections to be low, we focused on high specificity by 261 setting a conservative seropositivity threshold.

262 Most of the COVID-19 vaccinated participants in the current study were healthcare workers 263 who received Pfizer/BioNTech. IgG to Spike S1 after two doses showed comparable levels as those 264 for healthcare workers from another study conducted in Rotterdam, the Netherlands [24], while a 265 previously exposed population already produced robust IgG after one dose of Pfizer/BioNTech 266 vaccine. Interestingly, the majority of the previously infected participants receiving one vaccination 267 dose got infected approximately 11 months prior to vaccination (72%, 18/25). This suggests that 268 infection up to a year prior to vaccination still enables robust boosting of IgG to Spike S1 as observed 269 by others [25, 26], though numbers were small and nearly all were symptomatic. We confirmed that 270 Nucleoprotein also detects past SARS-CoV-2 infection in the previous five months in this vaccinated 271 population (77%), though the confidence interval was wide due to the low numbers available.

272 There are strengths and weaknesses in the cohorts we used in this study. Study team nurses 273 collecting samples and questionnaire data at pre-set sampling timepoints is the strength of the 274 household cohort, but its weakness includes that results are likely to correlate within families (i.e., 275 genetic relatedness and immune response). The national cohort is more representative of the 276 general population, including more asymptomatic individuals, and the repeated cross-sectional 277 design ensured that participants were included with different time frames since infection and/or 278 vaccination. However, the weakness of this approach is that it relied on self-reported data. Several 279 types of bias may arise from self-reported data including recall bias, e.g. those who tested SARS-CoV-280 2 positive might be more likely to remember the type of symptoms or test they received.

In conclusion, we showed that Nucleoprotein can detect prior SARS-CoV-2 infections with a
 sensitivity of 85% in a mildly symptomatic unvaccinated population between two weeks and two
 months after symptom onset. Serological responses to Nucleoprotein may thus prove helpful in
 identifying the frequency of SARS-CoV-2 infections in vaccinated persons, alongside molecular tests.
 Furthermore, it can help to interpret IgG to Spike S1 responses after COVID-19 vaccination as
 particularly high responses shortly after vaccination could be explained by prior exposure history.

287 Funding

288 This work was supported by the Dutch Ministry of Public Health, Welfare, and Sports (VWS).

289 Acknowledgments

- 290 We would like to thank all study participants and the team at the laboratory conducting all RT-qPCR
- assays, represented by Bas van der Veer, Sharon van den Brink and Anne-Marie van den Brandt.

292 **Conflict of interest**

293 The authors declare no competing interests.

294 References

295	1.	Dong, E., H. Du, and L. Gardner, An interactive web-based dashboard to track COVID-19 in
296		<i>real time.</i> Lancet Infect Dis, 2020. 20 (5): p. 533-534.
297	2.	Polack, F.P., et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J
298		Med, 2020. 383 (27): p. 2603-2615.
299	3.	Sheikh, A., et al., SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital
300		admission, and vaccine effectiveness. Lancet, 2021. 397 (10293): p. 2461-2462.
301	4.	den Hartog, G., et al., SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A
302		Multiplex Analysis Approach Accounting for Accurate Seroprevalence. J Infect Dis, 2020.
303		222 (9): p. 1452-1461.
304	5.	den Hartog, G., et al., Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a
305		nationwide prospective study. Clin Infect Dis, 2021.
306	6.	Fenwick, C., et al., Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses
307		Impact the Estimates of Infections in Population-Based Seroprevalence Studies. J Virol, 2021.
308		95 (3).
309	7.	Marien, J., et al., Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for
310		antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay. J
311		Virol Methods, 2021. 288 : p. 114025.
312	8.	Rosado, J., et al., Multiplex assays for the identification of serological signatures of SARS-
313		CoV-2 infection: an antibody-based diagnostic and machine learning study. Lancet Microbe,
314		2021. 2 (2): p. e60-e69.
315	9.	Fotis, C., et al., Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen
316		<i>assays</i> . Sci Rep, 2021. 11 (1): p. 6614.
317	10.	Dan, J.M., et al., Immunological memory to SARS-CoV-2 assessed for up to 8 months after
318		<i>infection.</i> Science, 2021. 371 (6529).
319	11.	Wu, Z. and J.M. McGoogan, Characteristics of and Important Lessons From the Coronavirus
320		Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the
321		Chinese Center for Disease Control and Prevention. JAMA, 2020. 323 (13): p. 1239-1242.
322	12.	McDonald, S.A., et al., Estimating the asymptomatic proportion of SARS-CoV-2 infection in
323		the general population: Analysis of nationwide serosurvey data in the Netherlands. Eur J
324		Epidemiol, 2021.
325	13.	Reukers, D.F.M., et al., High infection secondary attack rates of SARS-CoV-2 in Dutch
326		households revealed by dense sampling. Clin Infect Dis, 2021.
327	14.	Vos, E.R.A., et al., Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors
328		in the general population of the Netherlands during the first epidemic wave. J Epidemiol
329		Community Health, 2020.
330	15.	Vos, E.R.A., et al., Associations between measures of social distancing and SARS-CoV-2
331		seropositivity: a nationwide population-based study in the Netherlands. Clin Infect Dis, 2021.
332	16.	Verberk, J.D.M., et al., Third national biobank for population-based seroprevalence studies in
333		the Netherlands, including the Caribbean Netherlands. BMC Infect Dis, 2019. 19 (1): p. 470.
334	17.	Corman, V.M., et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.
335		Euro Surveill, 2020. 25 (3).
336	18.	World Health Organization. First WHO International Standard for anti-SARS-CoV-2
337		<i>immunoglobulin (human)</i> . 2020 [cited 2021 7 June 2021]; Available from:
338		https://www.nibsc.org/documents/ifu/20-136.pdf.
339	19.	R Core Team, R: A language and environment for statistical computing. 2020, R Foundation
340		for Statistical Computing: Vienna, Austria.
341	20.	Robin, X., et al., pROC: an open-source package for R and S+ to analyze and compare ROC
342		<i>curves</i> . BMC Bioinformatics, 2011. 12 : p. 77.

- Vanshylla, K., et al., *Kinetics and correlates of the neutralizing antibody response to SARS- CoV-2 infection in humans.* Cell Host Microbe, 2021.
- Choudhry, N., et al., *Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK.* Front Med (Lausanne), 2021. 8: p. 642723.
- Wheatley, A.K., et al., *Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19.* Nat Commun, 2021. 12(1): p. 1162.
- 34924.Geers, D., et al., SARS-CoV-2 variants of concern partially escape humoral but not T-cell350responses in COVID-19 convalescent donors and vaccinees. Sci Immunol, 2021. 6(59).
- 35125.Favresse, J., et al., Early antibody response in health-care professionals after two doses of352SARS-CoV-2 mRNA vaccine (BNT162b2). Clin Microbiol Infect, 2021.
- Abu Jabal, K., et al., Impact of age, ethnicity, sex and prior infection status on
 immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: realworld evidence from healthcare workers, Israel, December 2020 to January 2021. Euro
 Surveill, 2021. 26(6).

357

358 Tables

SARS-CoV-2 positive SARS-CoV-2 negative % (n) Ν* 352 1,161 61.1% (215) 60.5% (702) Female Age category (years) 1-21 17.1% (60) 16.0% (186) -22-65 71.0% (250) 68.4% (794) -66-87 11.9% (42) 15.6% (181) -COVID-19 related symptoms** -No 10.2% (36) 43.6% (506) -Yes 89.8% (316) 56.4% (655)

359 Table 1: General description of the RT-qPCR-confirmed SARS-CoV-2 study population.

360 *See Supplementary Figure 2A and 2B for more information on sample availability and exclusion

361 criteria. **Fever, coughing, shortness of breath, loss of taste or smell, sore throat, headache, pain

362 while breathing, runny nose, muscle ache, diarrhoea, (extreme) tiredness and/or nausea.

363 Table 2: General description of the COVID-19 vaccinated study population.

	% (n)
	unless otherwise specified
N*	230
Female	75% (172)
Age category in years	
- 18-65	77 (177)
- 66-91	23% (53)
Healthcare worker	75% (172)
Vaccination	
- Two doses	51% (118)
- Median days since first vaccination, range (IQR)	24, 0-59 (14-32)
Past SARS-CoV-2 infection	
- No	78% (179)
- (Self-reported) RT-qPCR positive	14% (32)
- Seroconversion lgG to Spike S1 prior to vaccination	8% (19)

364

*See Supplementary Figure 2A and 2B for more information on sample availability and exclusion

365 criteria. **Fever, coughing, shortness of breath, loss of taste or smell, sore throat, headache, pain

366 while breathing, runny nose, muscle ache, diarrhoea, (extreme) tiredness and/or nausea.

367 IQR: interquartile range; IgG: immunoglobulin G.

368

369 Figure legends

- Figure 1: Nucleoprotein and Spike S1 IgG responses to detect SARS-CoV-2 infections. In (A) IgG measurements to Nucleoprotein and Spike S1 are shown by SARS-CoV-2 PCR status and symptom status along with the threshold for seropositivity (dashed horizontal line). In (B) specificity and sensitivity estimates with 95% confidence intervals are shown for Nucleoprotein and Spike S1 seropositivity. In (C) sensitivity estimates with 95% confidence intervals of Nucleoprotein and Spike S1 seropositivity over time (in months); this does not include repeated samples from the same individuals. S1: Spike S1, N: Nucleoprotein, IgG: immunoglobulin G, BAU/ml: binding antibody units.
- 377

378 Figure 2: Nucleoprotein and Spike S1 IgG kinetics following COVID-19 vaccination. IgG

- 379 measurements to Spike S1 (A) and Nucleoprotein (B) in naïve individuals are shown over days since
- 380 first vaccination. In (C) IgG measurements to Spike S1 are shown by prior exposure status and
- number of doses received, individuals were included if they were sampled \geq 14 days after the first
- dose or \geq 7 days after the second dose. In (A-C) the dashed horizontal line depicts the threshold for
- 383 seropositivity. S1: Spike S1, N: Nucleoprotein, IgG: immunoglobulin G, BAU/ml: binding antibody
- 384 units.





